Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:QURE NASDAQ:SRRK NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$41.20-1.3%$43.75$19.44▼$53.27$2.99B2.18641,875 shs596,284 shsQUREuniQure$16.33+0.4%$14.67$4.45▼$19.18$892.14M0.11832,373 shs710,727 shsSRRKScholar Rock$32.65-1.9%$35.66$6.76▼$46.98$3.20B0.481.98 million shs1.42 million shsXENEXenon Pharmaceuticals$38.71+0.3%$33.83$26.74▼$46.00$2.98B1.16981,668 shs677,575 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics-1.21%-1.97%-4.46%+41.72%-13.95%QUREuniQure+3.24%+4.57%+18.86%+11.68%+168.10%SRRKScholar Rock-3.45%-3.79%-10.71%+14.25%+268.14%XENEXenon Pharmaceuticals-0.69%+1.10%+25.04%+34.40%-3.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKYMRKymera Therapeutics3.0461 of 5 stars4.61.00.00.03.12.50.0QUREuniQure2.3687 of 5 stars3.51.00.00.02.62.50.6SRRKScholar Rock4.509 of 5 stars4.60.00.04.42.93.30.6XENEXenon Pharmaceuticals2.2528 of 5 stars3.51.00.00.03.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 3.11Buy$58.7642.63% UpsideQUREuniQure 3.00Buy$37.45129.36% UpsideSRRKScholar Rock 3.20Buy$45.7540.12% UpsideXENEXenon Pharmaceuticals 3.00Buy$53.2037.43% UpsideCurrent Analyst Ratings BreakdownLatest QURE, SRRK, KYMR, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.008/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$50.008/14/2025QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$30.008/12/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.008/12/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$57.00 ➝ $55.008/12/2025XENEXenon PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.008/7/2025SRRKScholar RockBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$57.00 ➝ $45.007/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$47.007/30/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$60.007/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetStrong-Buy$53.007/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$47.07M62.58N/AN/A$13.59 per share3.03QUREuniQure$27.12M33.04N/AN/A($0.07) per share-233.29SRRKScholar Rock$33.19M94.57N/AN/A$2.43 per share13.44XENEXenon Pharmaceuticals$9.43M316.54N/AN/A$8.22 per share4.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest QURE, SRRK, KYMR, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A8.328.32QUREuniQure1.539.989.98SRRKScholar Rock0.216.336.33XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/AQUREuniQure78.83%SRRKScholar Rock91.08%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics16.01%QUREuniQure4.79%SRRKScholar Rock13.30%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableQURE, SRRK, KYMR, and XENE HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 29 at 4:10 PM | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 29 at 4:01 PM | globenewswire.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Affinity Asset Advisors LLCAugust 28 at 9:02 AM | marketbeat.comRussell Investments Group Ltd. Has $2.53 Million Stock Position in Xenon Pharmaceuticals Inc. $XENEAugust 27 at 3:39 AM | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by T. Rowe Price Investment Management Inc.August 26 at 4:49 AM | marketbeat.comEntryPoint Capital LLC Makes New $298,000 Investment in Xenon Pharmaceuticals Inc. $XENEAugust 25, 2025 | marketbeat.comDid Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?August 24, 2025 | finance.yahoo.comWellington Management Group LLP Has $127.13 Million Position in Xenon Pharmaceuticals Inc. $XENEAugust 24, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Atika Capital Management LLCAugust 23, 2025 | marketbeat.comCandriam S.C.A. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENEAugust 23, 2025 | marketbeat.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)August 23, 2025 | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLCAugust 22, 2025 | marketbeat.comAn Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% UndervaluedAugust 21, 2025 | finance.yahoo.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plcAugust 21, 2025 | marketbeat.comLord Abbett & CO. LLC Sells 106,990 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)August 19, 2025 | marketbeat.comWhat is Chardan Capital's Forecast for XENE FY2025 Earnings?August 19, 2025 | marketbeat.comFY2025 Earnings Estimate for XENE Issued By Chardan CapitalAugust 18, 2025 | americanbankingnews.comXENE FY2025 EPS Estimate Decreased by Cantor FitzgeraldAugust 16, 2025 | marketbeat.comHC Wainwright Analysts Decrease Earnings Estimates for XENEAugust 16, 2025 | marketbeat.comQ3 EPS Estimate for Xenon Pharmaceuticals Lifted by AnalystAugust 16, 2025 | marketbeat.comWilliam Blair Has Negative Estimate for XENE Q3 EarningsAugust 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE, SRRK, KYMR, and XENE Company DescriptionsKymera Therapeutics NASDAQ:KYMR$41.20 -0.55 (-1.32%) Closing price 04:00 PM EasternExtended Trading$41.78 +0.58 (+1.41%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.uniQure NASDAQ:QURE$16.33 +0.07 (+0.43%) Closing price 04:00 PM EasternExtended Trading$16.58 +0.25 (+1.53%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Scholar Rock NASDAQ:SRRK$32.65 -0.63 (-1.89%) Closing price 04:00 PM EasternExtended Trading$32.65 0.00 (0.00%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Xenon Pharmaceuticals NASDAQ:XENE$38.71 +0.11 (+0.28%) Closing price 04:00 PM EasternExtended Trading$38.70 -0.02 (-0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access